Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Crump

Showing results (131-140 of 183) with videos related to

Pageof 19
Sort By:
Blood Advances|May 13, 2020
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORALSarit Assouline, Shen Li, Christian Gisselbrecht, et al.
British Journal of Haematology|June 9, 2020
Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphomaLourdes Calvente, Rosemarie Tremblay-LeMay, Wei Xu, et al.
Leukemia & Lymphoma|October 11, 2018
A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†Tony Reiman, Kerry J Savage, Michael Crump, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trialsDonald A Berry, Naoto T Ueno, Marcella M Johnson, et al.
Blood|July 5, 2005
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosisBronno van der Holt, Bob Löwenberg, Alan K Burnett, et al.
The New England Journal of Medicine|December 14, 2011
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphomaRalph M Meyer, Mary K Gospodarowicz, Joseph M Connors, et al.
Blood|August 5, 2017
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyMichael Crump, Sattva S Neelapu, Umar Farooq, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II StudyTycel Jovelle Phillips, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Hematological Oncology|March 3, 2026
Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR TInna Y Gong, Meenakshi Jeeva, Katrina Hueniken, et al.
Leukemia & Lymphoma|May 16, 2017
Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study<sup></sup>Tanya Skamene, Michael Crump, Kerry J Savage, et al.
Pageof 19

Showing results (131-140 of 183) with videos related to

Sort By:
Pageof 19
Blood Advances|May 13, 2020
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORALSarit Assouline, Shen Li, Christian Gisselbrecht, et al.
British Journal of Haematology|June 9, 2020
Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphomaLourdes Calvente, Rosemarie Tremblay-LeMay, Wei Xu, et al.
Leukemia & Lymphoma|October 11, 2018
A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†Tony Reiman, Kerry J Savage, Michael Crump, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trialsDonald A Berry, Naoto T Ueno, Marcella M Johnson, et al.
Blood|July 5, 2005
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosisBronno van der Holt, Bob Löwenberg, Alan K Burnett, et al.
The New England Journal of Medicine|December 14, 2011
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphomaRalph M Meyer, Mary K Gospodarowicz, Joseph M Connors, et al.
Blood|August 5, 2017
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyMichael Crump, Sattva S Neelapu, Umar Farooq, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II StudyTycel Jovelle Phillips, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Hematological Oncology|March 3, 2026
Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR TInna Y Gong, Meenakshi Jeeva, Katrina Hueniken, et al.
Leukemia & Lymphoma|May 16, 2017
Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study<sup></sup>Tanya Skamene, Michael Crump, Kerry J Savage, et al.
Pageof 19